Efficacy and safety of injectable quinine for the treatment of malaria in Japan

Efficacy and safety of injectable quinine for the treatment of malaria in Japan - Efficacy and safety of injectable quinine for the treatment of malaria in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027485

Enrollment

Registered

2017-05-25

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malaria

Interventions

Administer injectable quinine for the treatment of malaria (8.3 mg base/kgBW, 16.6 mg for loading)in 500 mL of 5% glucose or physiological saline, for upto 7 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe malaria patients or malaria patients who cannot take oral anti-malaria drugs, who agree to join the study.

Exclusion criteria

Exclusion criteria: 1) Patients who are allergic to injectable quinine or related compounds 2) Patients who do not agree to give written informed consent 3) Patients principal who investigator considers inappropriate

Design outcomes

Primary

Measure	Time frame
cure rate	—

Secondary

Measure	Time frame
1) time required for fever disappearance 2) parasite clearance time 3) recurrence after 28 days of treatment	—

Countries

Japan

Contacts

Public ContactMizoguchi Ayami

University of Miyazaki Faculty of Medicine

ayami_mizoguchi@med.miyazaki-u.ac.jp0985-85-0990

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026